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Abstract
Oxidative stress (OS) is implicated as a unifying factor between chronic kidney 
diseases and cardiovascular diseases. The objective of the study was to compare the 
oxidant and antioxidant status in patients with PD according to the state of DM. 
Lipoperoxides (LPO), 8-isoprostanes (8-IP) and nitric oxide (NO) were determined 
as oxidants and the activity of superoxide dismutase (SOD) and total antioxidant 
capacity (TAC) as antioxidants in patients with DM and without DM (No-DM). 
We included 35 patients with DM, 42 No-DM patients and 10 healthy people as 
a control group (HC). Patients with DM were older (p<0.0001), had higher BMI 
(p<0.0001), high glucose levels (p<0.0001) and more hypertension (p<0.0001). 
It was found that LPO levels increased in patients with DM and No-DM vs. HC 
(p<0.0001). There was a decrease in the levels of 8-IP in DM and No-DM compared 
to HC (p<0.0001). The levels of NO in patients with DM and No-DM decreased 
significantly compared to the HC group with 197.97±34.20 μM (p<0.0001). The 
activity of the SOD enzyme in patients with DM and No-DM was found to be 
increased compared to the HC group (p<0.0001). The levels of TAC in HC were 
2.62±0.17 mM and decreased in patients with DM and No-DM (p<0.0001).
Keywords: end-stage renal disease, chronic kidney disease, peritoneal dialysis, 
diabetes mellitus, oxidative stress, antioxidants
1. Introduction
Several traditional and nontraditional cardiovascular risk factors have been 
described in chronic kidney disease (CKD). Cardiovascular disease (CVD) still is the 
leading cause of death among end-stage renal disease (ESRD) patients. CVD and 
CKD are closely related to each other, and the disease of one of the organs causes 
dysfunction of the other by conditioning the failure of both organs [1]. CKD patients 
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generally have several traditional cardiovascular risk factors like diabetes mellitus 
(DM), dyslipidemia, and arterial hypertension. These conditions are associated with 
oxidative stress (OS), and these can trigger and accelerate the progression of renal 
injury [2]. OS is defined as the imbalance between oxidants and the antioxidant 
defenses of the body. Reactive oxygen species (ROS) are generated through enzymes 
such as nicotinamide phosphate adenine dinucleotide (NADPH) oxidase, which 
reduces oxygen to superoxide anion (O2−). This anion is converted to hydrogen per-
oxide (H2O2) by the enzyme superoxide dismutase (SOD). The O
2− anion reacts with 
nitric oxide (NO) by producing peroxynitrite (nitrosative stress). The H2O2 reacts 
with intracellular iron to form the hydroxyl radical. In addition, H2O2 is catalyzed to 
hypochlorous acid in the presence of the chloride ion, by myeloperoxidase activity. 
Uremic toxins also participate by increasing ROS generation. The excessive produc-
tion of ROS is able to oxidize lipids, proteins, and nucleic acids [3].
DM is a frequent cause of the need for renal replacement therapy (RRT) [4]. 
In Jalisco (Mexico), nearly half of the patients in dialysis are on peritoneal dialysis 
(PD), and almost half of these patients have DM [5]. In 2009, it was reported that 
diabetic nephropathy (DN) causes ~44% of all cases of ESRD in the United States 
[6]. DM contributes, in large part, to the high costs of health care and the increase 
in mortality from the increased incidence of DN that leads to ESRD [7]. The 
purpose of the study was to compare the oxidants and antioxidants state in patients 
with PD according to DM status.
2. Patients and methods
A single-center, analytical cross-sectional study was performed with ESRD 
patients on PD. Patients were eligible if they were 16 years old or older and were 
incident or prevalent in the population of the PD program and never have had a 
peritoneal equilibrium test (PET) performed before or if the last PET result was 
older than 1 year. We exclude patients with a current or a previous peritonitis epi-
sode in the last 6 months, patients with PD catheter dysfunction, and patients with 
a current infectious, inflammatory, and malignant process or impaired glycemic 
control (serum glucose > 200 mg/dL). We collected information about PD treat-
ment and doses, residual diuresis, ultrafiltration, and the value of D/P creatinine 
(creatinine ratio in the dialysis fluid and plasma), reported at 4 h at the end of the 
PET. The type of peritoneal transport is determined by the result obtained, modal-
ity and the dialysis glucose solution concentration [8].
2.1 Oxidative stress markers
For measurement of OS markers, 10 mL of blood samples were drawn when 
PET blood samples were taken, 5 mL with 0.1% of ethylenediaminetetraacetic 
acid (EDTA) tube and other 5 mL in dry tube. The blood was immediately centri-
fuged at 10,000 rpm for 10 min at room temperature; supernatants were stored in 
aliquots at −80°C until their final processing. We included 10 mL of extra blood 
from 10 blood donors (healthy control) that was used to establish the normal value 
of the reagents.
2.1.1 Lipoperoxides (LPO)
The levels of LPO in plasma were measured through the FR22 assay kit 
(Oxford Biomedical Research Inc., Oxford, MI, USA®) according to the 
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manufacturer’s instructions. The limit of detection for this test was 0.1 nmol/
mL. The chromogenic reagent reacts with malondialdehyde (MDA) and 
4-hydroxy-alkenals to form a stable chromophore. First, 140 μL of plasma with 
455 μL of N-methyl-2-phenylindole in acetonitrile (Reagent 1) was diluted with 
ferric iron in methanol. Samples were agitated; after which 105 μL 37% HCl 
was added followed by incubation at 45°C for 60 min and centrifugation at 
12,791 rpm for 10 min. Next, 150 μL of the supernatant was added, and absor-
bance was measured at 586 nm. The pattern curve with known concentrations 
of 1,1,3,3-tetramethoxypropane in Tris–HCl was used. The intra-assay CV was 
8.5% [9].
2.1.2 8-Iso-prostaglandin F2α 8-isoprostanes (8-IP)
The immunoassay reagent kit from Cayman Chemical Company® (Michigan, 
USA) was used according to the manufacturer’s instructions. The limit of detection 
was 0.8 pg/mL. The 8-IP assay was based on the principle of competitive binding 
between samples 8-IP, 8-IP acetylcholinesterase (AChE) conjugate, and 8-IP tracer. 
Then, 50 μL of samples or standard was added to each well, and 50 μL of 8-IP AChE 
tracer was added to all wells except the total activity and blank wells; and 50 μL of 
8-IP enzyme immunoassay antiserum was added to all wells except the total activity 
and blank wells. At once, 50 μL of 8-IP antiserum was added to all wells except total 
activity, non-specific binding, and blank wells. The plate was covered and incu-
bated at 4 °C for 18 h and then washed 5 times with buffer. Absorbance was read at 
420 nm. The intra-assay CV was 12.5% [10].
2.1.3 Nitric oxide (NO)
Prior to the determination of the NO levels, the serum samples were deprot-
einized by the addition of 6 mg of zinc sulfate to 400 μL of sample and vortexed 
for 1 minute and the samples were centrifuged at 10,000×g for 10 min at 4°C. For 
the determination of ON, the colorimetric method was used according to the 
kit (Nitric Oxide Assay Kit, NB98, Oxford Biomedical Research®). About 85 μL 
of the standard or sample was added to the wells of the plate, 10 μL of nitrate 
reductase was added to each well, and 10 μL of 2 mM NADH was added to the 
wells. The plate was stirred for 20 min at room temperature. Then 50 μL of dye 
1 was added and stirred briefly and then 50 μL of dye 2, and again the samples 
were vortexed for 5 min at room temperature. Finally, the plate was read at 
540 nm in a spectrophotometer within the first 20 minutes of completion of the 
procedure [11].
2.2 Antioxidants
2.2.1 Superoxide dismutase (SOD)
We followed the kit manufacturer’s instructions (SOD No. 706002, Cayman 
Chemical Company®, USA) for the detection of O2
− generated by the xanthine 
oxidase and hypoxanthine enzymes through the reaction of tetrazolium salts. We 
diluted the serum samples 1:5 in the sample buffer, 200 μL of the radicals’ detector 
(1:400 dilution), and added 10 μL of the sample. After slow agitation, 20 μL of 
xanthine oxidase was then added to the wells. Then, the microplate was incubated 
for 20 minutes at room temperature. The absorbency was read at 440 wavelength of 
nm. The levels are reported in IU/mL [12].
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2.2.2 Total antioxidant capacity (TAC)
The evaluations of TAC were made following the instructions of the kit manu-
facturer (Total Antioxidant Power Kit, No. TA02.090130, Oxford Biomedical 
Research®), to obtain the concentration in mM equivalents of uric acid. The detection 
limit was 0.075 mM. The samples and standards were diluted 1:40, and 200 μL was 
placed in each well. The plate was read at 450 nm as a reference value, 50 μL of copper 
solution was added, and the plate was incubated at room temperature for 3 minutes. 
Afterward, 50 μL of stop solution was added and the plate was read at 450 nm. The 
dilution factor was considered in the result. The intra-assay CV was 7.8% [13].
2.3 Statistical analysis
Normally distributed variables were presented as mean ± standard deviation (SD); 
skewed variables were exhibited as median with interquartile range (IQR). Categorical 
variables were expressed as frequency and percentage. All demographic and PD-related 
characteristics were compared between diabetics and nondiabetic patients using Chi2, 
Student’s t test, or Mann-Whitney U test accordingly to the type of data distribution. 
When significant differences in serum levels of oxidative stress markers were found 
between groups and were feasible, we conducted a multivariable analysis, to determine 
the interaction between DM and other factors associated with increased OS. The statis-
tical analyses were performed using the IBM SPSS v.18 software (Chicago, IL, USA). For 
all the analysis, a p ≤ 0.05 value was considered as statistically significant.
2.4 Ethics considerations
The scientific research study abides by the regulations of the internationally 
established guidelines of the Declaration of Helsinki 1964, revised in October 2013 
at the World Medical Assembly. All procedures were performed according to regula-
tions stipulated in the General Health Legal Guidelines for Healthcare Research 
in Mexico, 2nd Title, in Ethical Aspects for Research in Human Beings, Chapter 1, 
Article 17. The study was evaluated and approved by the Local Ethics and Research 
Committee at the Regional General Hospital No. 46, Mexican Institute of Social 
Security, Guadalajara, Jalisco, Mexico, with registration number R-2017-1303-117. 
All patients gave and signed the informed consent form in the presence of signed 
witnesses. Patients had the right to withdraw from the study at any time without 
representing harm to the patient-doctor relationship and without affecting their 
treatment. At all times, total confidentiality was maintained, and the patients were 
informed of the results throughout the study.
3. Results
Seventy-seven patients were included in the study, 35 with DM and 42 No-DM 
patients. The median age was 42 years. There was a greater prevalence of male-
gendered patients, DM 62.86% and No-DM 76.19%. DM patients were older 
(p < 0.0001) and had higher body mass index (p < 0.0001), with significant 
increase in glucose (p < 0.0001) and more prevalence of arterial hypertension 
(p < 0.0001). A total of 63 patients used erythropoiesis-stimulating agents, with 
a mean dose of 140 ± 63.6 UI/kg/week, and a major dose was observed in No-DM 
patients. In Table 1, the demographic and biochemical results of the patients 
are shown. Significant increases in DM patients were found in triglyceride levels 
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(p < 0.046), very-low-density cholesterol (VLDL) (p < 0.05) and highly specific 
reactive C protein (RCP) (p < 0.034), which suggests systemic inflammation. 
However, phosphorus (p < 0.0001) and albumin (p < 0.0001) were found to be 
decreased. No-DM patients showed better biochemical results in urea (p < 0.0001), 
creatinine (p < 0.0001), magnesium (p < 0.009), and potassium (p < 0.047).
3.1 Dialysis characteristics
The patients had a median vintage on PD of 13 months (4–26), without dif-
ferences between DM and No-DM. In addition, there were no differences in the 
DM, n = 35 No-DM, n = 42 p
Gender n (%)
Male 22 (62.86) 32 (76.19) 0.377
Female 13 (37.14) 10 (23.81) 1
Age, years 62 (54.5–66.5) 28 (25–37) <0.0001*
Weight, kg 73.16 ± 11.60 67.25 ± 12.52 0.011**
Height, m 1.62 ± 0.09 1.66 ± 0.08 0.046**
BMI, kg/m2 27.80 ± 4.56 24.52 ± 4.29 <0.0001**
Hypertension, n (%) 34 (97.14) 5 (11.90) <0.0001 ŧ
Residual uresis, mL 500 (250–1000) 500 (57.5–1000) 0.85
Hemoglobin, g/dL 11.41 ± 1.80 10.83 ± 2.33 0.16
Urea, mg/dL 102.63 ± 30.95 124.39 ± 31.16 <0.0001**
Creatinine, mg/dL 7.86 ± 3.07 13.89 ± 4–10 <0.0001**
Glucose, mg/dL 131 (98–157) 95 (88.7–103) <0.0001*
Phosphorus, mg/dL 4.11 ± 1.42 5.63 ± 1.70 <0.0001**
Calcium, mg/dL 8.76 ± 0.97 8.73 ± 0.92 0.35
Magnesium, mg/dL 2.13 ± 0.48 2.33 ± 0.41 0.023**
Potassium, mEq/L 4.20 ± 0.73 4.47 ± 0.58 0.032**
Sodium, mEq/L 138 (136–140) 140 (137–141) 0.06
Albumin, g/dL 3.17 ± 0.59 3.80 ± 0.53 <0.0001**
Uric acid, mg/dL 6.22 ± 1.23 6.68 ± 1.39 0.08
Iron, mcg/dL 73.35 ± 26.34 77.49 ± 40.85 0.87
TSAT % 35.30 ± 17.86 32.5 ± 23.44 0.41
Cholesterol, mg/dL 171.51 ± 51.21 170.27 ± 43.38 0.91
HDL, mg/dL 41.55 ± 13.64 45.29 ± 15.34 0.28
LDL, mg/dL 93.12 ± 36.35 100.11 ± 35.46 0.45
Triglycerides, mg/dL 150 (98–219.6) 124 (88–158) 0.046*
VLDL, mg/dL 30 (19.75–45.75) 24.5 (17.5–32.2) 0.049*
HCO3, mEq/L 20.33 ± 3.27 21.57 ± 3.24 0.17
RCP, mg/L 3.31 (1.41–9.64) 1.98 (1–4.36) 0.034*
Values are mean ± standard deviation (SD), percentage (%) or median (25–75th percentile), and ŧChi2 test  
*Mann-Whitney U test; **Student’s t test.
DM, diabetes mellitus; No-DM, without DM; BMI, body mass index; TSAT, transferrin saturation; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; HCO3, bicarbonate; RCP, 
reactive C protein.
Table 1. 
Demographic and biochemical results in patients with ESRD in PD with and without diabetes mellitus
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glucose concentration used in the dialysis solutions, but DM patients were less likely 
to be on automated peritoneal dialysis (APD) modality (p = 0.016), and the median 
dwell time was 16 h (QR 16–24). There were no differences in the D/P creatinine 
or the history of peritonitis between patients. The median residual diuresis was 
500 mL/day (250–1000), and there were no difference in the volume of urine or the 
number of patients with significant residual diuresis. The peritoneal ultrafiltration 
and the total ultrafiltration were similar in both DM and No-DM patients (p = 0.54 
and 0.72, respectively) and were within guidelines and recommendations.
3.2 Oxidants
3.2.1 Lipoperoxides, 8-iso-prostaglandin F2α (8-IP), and nitric oxide
The levels of LPO (MDA and 4-hydroxy-alkenals) in the healthy controls were 
3.05 ± 0.18 μM. However, LPO levels were found to be increased in DM patients, 
136.95 ± 18.17 μM (p < 0.0001), and 194.18 ± 54.70 μM (p < 0.0001) in No-DM 
patients. No significant difference was found between patients with and without DM.
The serum levels of 8-IP in DM patients were found to be decreased 
5.36 ± 0.80 pg/mL (p < 0.0001) and No-DM 9.99 ± 6.41 pg/mL (p < 0.0001) versus 
the levels that were obtained in healthy controls, 22.88 ± 3.80 pg/mL (p < 0.0001). 
No significant difference was found between patients with and without DM.
The levels of the NO products (nitrites/nitrates) in healthy controls were 
197.97 ± 34.20 μM. The products of NO in DM patients were found to be decreased, 
18.02 ± 3.41 μM (p < 0.0001), and No-DM, 12.96 ± 2.78 μM (p < 0.0001). There 
was no significant difference between patients with and without DM (Table 2 and 
Figure 1).
3.3 Antioxidants
3.3.1 Superoxide dismutase and total antioxidant capacity
An increase in the serum activity of SOD was found in patients in PD with DM, 
3.36 ± 0.28 U/mL, and No-DM, 3.28 ± 0.22 U/mL (p < 0.0001), versus the activity 
Healthy control No-DM p, MW-U DM p, MW-U
Antioxidants
SOD, U/mL 0.23 ± 0.015 3.28 ± 0.22 <0.0001 3.36 ± 0.28 <0.0001
Total 
antioxidant 
capacity, mM
2.62 ± 0.17 0.69 ± 0.23 <0.0001 0.65 ± 0.031 <0.0001
Oxidants
8-Isoprostane, 
pg/mL
22.88 ± 3.80 9.99 ± 6.41 <0.0001 5.36 ± 0.80 <0.0001
LPO, μM 3.05 ± 0.18 194.18 ± 54.70 <0.0001 136.95 ± 18.17 <0.0001
Nitric oxide, 
μM
197.97 ± 34.20 12.96 ± 2.78 <0.0001 18.02 ± 3.41 <0.0001
SOD, superoxide dismutase; LPO, lipoperoxides; No-DM, without diabetes mellitus; DM, diabetes mellitus; MW-U, 
Mann-Whitney U test.
Table 2. 
Antioxidants and oxidants with and without diabetes mellitus vs. healthy controls.
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of the enzyme in healthy controls, 0.23 ± 0.015 U/mL. There was no significant 
difference between patients with and without DM.
The serum levels found in healthy controls of TAC were 2.62 ± 0.17 mM; how-
ever, significantly decreased levels were found in DM patients, 0.65 ± 0.03 mM, and 
No-DM patients, 0.69 ± 0.23 mM (p < 0.0001). There was no significant difference 
between patients with and without DM (Table 2 and Figure 1).
3.4 Correlations in all patients
When including the results of all patients, positive correlation was found 
between LPO with total cholesterol, LDL, triglycerides, and VLDL cholesterol. 
The 8-IP showed positive correlation with the reactive C protein. The NO products 
obtained a positive correlation with Hb, LDL, triglycerides, and VLDL cholesterol. 
The activity of SOD showed a positive correlation with creatinine, magnesium, and 
HDL cholesterol. Negative correlation was found between the products of NO and 
HDL cholesterol. SOD activity showed negative correlation with residual urine, Hb, 
triglycerides, and VLDL cholesterol (Table 3).
3.5 Correlations in no-DM patients
When including the results according to status in No-DM patients, there was a 
positive correlation between 8-IP with hemoglobin, between NO with triglycerides 
and LDL cholesterol, between SOD with creatinine and phosphorus, and between 
TAC with phosphorus and uric acid. There was negative correlation between 
LPO and body weight, NO and HDL cholesterol, SOD with residual diuresis, hemo-
globin, triglycerides, and VLDL cholesterol (Table 4).
Figure 1. 
Levels of antioxidant and oxidant in DM and No-DM patients.
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3.6 Correlations in DM patients
In patients with DM, positive correlation was found between LPO, calcium, 
cholesterol, and triglycerides; between 8-IP with calcium and RCP; between NO 
and VLDL cholesterol and LDL cholesterol and triglycerides; between SOD with 
creatinine, magnesium, and HDL cholesterol; and between TAC with urea, uric 
acid, VLDL cholesterol, and PCR. There was only a negative correlation between 
SOD with triglycerides and VLDL cholesterol and also between total cholesterol and 
HDL cholesterol (Table 4).
r2 LPO 8-IP NO SOD TAC
Weight −0.12 0.05 0.02 0.06 0.03
Height −0.10 −0.13 −0.008 −0.01 0.12
BMI −0.05 0.15 0.04 0.08 −0.03
Residual urine −0.007 0.04 0.061 −0.31** −0.09
Hemoglobin 0.07 0.09 0.27* −0.38** −0.05
Urea −0.05 −0.01 −0.26* 0.08 0.36**
Creatinine −0.14 −0.14 −0.16 0.31** 0.23*
Glucose 0.12 0.03 0.20 0.06 0.14
Phosphorus −0.05 0.05 −0.31** 0.17 0.35**
Calcium 0.09 0.04 0.006 −0.21 0.03
Magnesium −0.08 0.14 −0.13 0.27* 0.07
Potassium −0.10 0.13 −0.18 0.14 0.09
Sodium 0.16 −0.04 −0.01 −0.09 0.03
Albumin 0.06 −0.15 0.01 −0.08 0.15
Uric acid −0.04 0.03 0.05 −0.06 0.52**
Iron −0.05 −0.05 −0.02 −0.04 0.07
TSAT −0.19 0.42 −0.08 −0.14 −0.07
Cholesterol 0.26* 0.02 0.15 −0.16 −0.08
HDL −0.05 −0.01 −0.44** 0.29* −0.21
LDL 0.27* 0.007 0.31* −0.14 0.06
Triglycerides 0.35** 0.04 0.52** −0.49** 0.04
VLDL 0.29* 0.07 0.52** −0.44** 0.08
HCO3 −0.07 −0.11 0.07 −0.03 0.03
RCP −0.12 0.37** 0.17 −0.19 0.08
*p < 0.05, **p < 0.01.
DM, diabetes mellitus; No-DM, without DM; BMI, body mass index; TSAT, transferrin saturation; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; HCO3, bicarbonate; RCP, 
reactive C protein; LPO, lipoperoxides; 8-IP, 8-isoprostanes; NO, nitric oxide; SOD, superoxide dismutase; TAC, total 
antioxidant capacity.
Table 3. 
Correlation between demographic, biochemical, and oxidative stress markers.
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r2 LPO 8-IP NO SOD TAC
No-DM patients in PD
Weight −0.34* 0.07 0.15 0.041 0.03
Height −0.22 0.01 0.28 0.043 0.06
BMI −0.26 0.06 0.03 0.005 0.01
Residual urine 0.06 0.20 0.08 −0.38* −0.05
Hemoglobin −0.09 0.32* 0.25 −0.49** −0.04
Urea −0.16 0.02 −0.26 0.22 0.28
Creatinine −0.15 −0.16 0.04 0.50** 0.28
Glucose −0.07 −0.06 0.13 0.19 0.10
Phosphorus −0.10 −0.21 −0.27 0.30* 0.46**
Calcium −0.13 0.06 −0.02 −0.18 −0.09
Magnesium −0.004 0.04 0.08 0.24 −0.10
Potassium −0.03 0.29 −0.13 0.22 0.23
Sodium 0.03 0.02 0.08 −0.02 −0.07
Albumin 0.08 0.18 0.27 −0.24 0.05
Uric acid −0.02 0.05 0.10 −0.17 0.51**
Iron −0.08 −0.15 −0.02 −0.08 0.22
TSAT −0.09 0.57 −0.06 −0.27 −0.16
Cholesterol 0.12 −0.05 −0.06 −0.07 −0.25
HDL 0.08 0.02 −0.44** 0.19 −0.08
LDL 0.06 −0.01 0.17 −0.07 −0.04
Triglycerides 0.22 0.04 0.46** −0.53** −0.12
VLDL 0.21 0.05 0.43** −0.48** −0.11
HCO3 −0.06 −0.08 0.14 −0.05 0.41
*
PCR −0.15 0.27 0.23 −0.11 −0.15
Diabetic patients in PD
Weight 0.14 −0.05 −0.27 0.03 0.12
Height 0.05 −0.22 −0.21 −0.06 0.08
BMI 0.06 0.12 −0.15 0.10 0.05
Residual urine −0.16 −0.16 −0.02 −0.21 −0.14
Hemoglobin 0.28 −0.21 0.23 −0.25 −0.02
Urea 0.13 0.03 −0.03 −0.03 0.36*
Creatinine −0.09 0.09 −0.17 0.39* 0.17
Glucose 0.23 −0.01 0.20 −0.05 0.27
Phosphorus 0.12 0.45** −0.17 0.07 0.19
Calcium 0.39* 0.04 0.11 −0.23 0.14
Magnesium −0.07 0.34 −0.25 0.35* 0.14
Potassium −0.19 0.05 −0.16 0.06 −0.09
Sodium 0.28 0.002 −0.06 −0.13 0.10
Albumin 0.26 −0.32 −0.02 0.07 0.13
Uric acid 0.01 0.01 0.16 0.04 0.53**
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4. Discussion
In this cross-sectional study, we compared levels of oxidative stress markers on 
PD patients with and without diabetes. The DM patients were older, had higher BMI, 
had more prevalence of hypertension, and had higher triglycerides and VLDL levels 
that corresponded to the classic metabolic syndrome [14]. The prevalence of meta-
bolic syndrome in patients with ESRD on PD is quite frequent, and its presence is 
reported in ~40–60% of patients with DN depending on the population studied [15].
DM is the main cause of ESRD and represents 58% of incident cases [16]. 
Several interventions have been suggested for the prevention and control of DM. A 
directed selection study is followed by a randomized controlled trial by groups, 
with randomization where participants were at risk for DM. The subjects received 
standard care or intervention. The intervention consisted of a group structured 
education program of 6 h with an annual update and regular telephone contact with 
follow-up for 3 years. About 29.1% attended all the sessions; 22.6% did not attend 
the education. The authors found a 26% reduction in the risk of type 2 DM of those 
who received the intervention compared with the standard care. They found no 
statistical significance, which suggests that the effectiveness of all interventions is 
not promising [17].
When the patient already has DM, a variety of risk factors that promote the 
development and progression of DN have been reported: persistent high glucose 
levels, time of duration of DM, arterial hypertension, obesity, endothelial dysfunc-
tion, and dyslipidemia. Most of these risk factors are modifiable through antidia-
betic, antihypertensive, lipid-lowering, and primarily lifestyle change [18]. It has 
been previously reported that patients with ESRD and DM who require dialysis 
have higher rates of various morbidities and worse clinical outcomes compared to 
non-DM patients. It has also been shown that glycemic decontrol is associated with 
more micro- and macrovascular complications, in addition to higher mortality [19].
In the present study, a significant increase in LPO was found in DM and No-DM 
patients undergoing PD vs. the levels found in healthy controls. It has been shown 
that patients in PD manifest excessive OS compared to healthy controls. OS in PD 
r2 LPO 8-IP NO SOD TAC
Iron 0.003 0.05 −0.007 0.05 −0.10
TSAT −0.65 0.21 −0.14 0.09 −0.06
Cholesterol 0.42** 0.08 0.42* −0.24 0.09
HDL −0.21 −0.03 −0.33 0.39* −0.38*
LDL 0.55** 0.05 0.52** −0.24 0.19
Triglycerides 0.46** 0.003 0.54** −0.46** 0.32
VLDL 0.34 0.04 0.57** −0.41* 0.35*
HCO3 −0.03 −0.14 0.09 −0.03 −0.20
RCP −0.03 0.50* 0.09 −0.38 0.44*
*p < 0.05, **p < 0.01.
DM, diabetes mellitus; No-DM, without DM; BMI, body mass index; TSAT, transferrin saturation; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; HCO3, bicarbonate; RCP, 
reactive C protein; LPO, lipoperoxides; 8-IP, 8-isoprostanes; NO, nitric oxide; SOD, superoxide dismutase; TAC, 
total antioxidant capacity.
Table 4. 
Correlation between demographic, bioquimical, and oxidative stress markers.
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is closely related to chronic inflammation, atherogenesis, peritoneal fibrosis, and 
loss of residual renal function. The unfavorable serum lipid profile and the chronic 
exposure of peritoneal cells to super-physiological levels of glucose in patients 
undergoing PD could increase glycosylation and lipid oxidation, favoring the 
increase of LPO and consequently greater OS [20]. When there is greater perme-
ability and biocompatibility of the peritoneal membrane, with better preserved 
residual renal function, it can be assumed that patients could have a lower oxidative 
load [21, 22]; however, reports in the literature indicate that the oxidative metabo-
lism of peripheral and peritoneal phagocytes is activated during PD with conven-
tional dialysate, by the products of glucose degradation, by low pH, and by high 
osmolarity [23]. The bio-incompatibility of DP solutions seems to play a central role 
in increasing ROS production [24]. Previously increased OS in patients with ESRD 
in RRT has been reported before undergoing kidney transplantation [25].
In the results obtained in the patients undergoing PD with DM and No-DM, the 
8-IP were significantly diminished versus the healthy controls; possibly, the clearance 
of this marker by PD participates in the decrease of serum levels. Previous reports 
have shown that the residual glomerular filtration rate is independently associated 
with the levels of advanced glycation end products in plasma effluents and perito-
neum [26]. It has been previously reported that DM is associated with increased lipid 
peroxidation and persistent platelet activation with increased in vivo formation of 
F2-isoprostane 8-iso-prostaglandin (PG) F2alfa (bioactive product of arachidonic 
acid peroxidation). 8-IP improves their levels in presence of DM by contributing to 
platelet activation related to altered glycemic control and increased lipid peroxidation 
by providing an important biochemical link between altered glycemic control and 
persistent platelet activation [27]. However, in our study this marker was found to be 
significantly decreased in serum in both DM and No-DM patients in inverse rela-
tion to published reports where they found increased levels in urine [18]. Kant et al. 
mentioned that when lipid peroxidation products were elevated in the prediabetic 
stage, the determination of this marker is useful in the detection of patients at risk of 
type 2 DM [28]. In this study, the 8-IP in residual urine was not measured.
In patients with DM and No-DM, we found significantly decreased serum levels of 
NO. NO is a potent biological vasodilator produced by the vascular endothelium from 
L-arginine. NO is synthesized by endothelial NO synthase (eNOS). Vascular NO defi-
ciency may be involved in accelerated atherosclerosis and the dramatic cardiovascular 
mortality observed in patients with CKD [29]. Vascular changes can induce OS and 
inflammation, favoring the probability of morbidity and mortality by aggravating 
CVD [30]. In CKD, endothelial dysfunction is characterized by the altered capacity of 
the vascular endothelium to stimulate vasodilation. NO plays a key role in the devel-
opment of atherosclerosis in this pathology. The decrease in the bioavailability of NO 
is a key factor of endothelial dysfunction. In addition, NO plays an important role in 
the protection of the vascular wall because it induces its own metabolic products [31].
In the present study, a significant increase in the activity of the SOD enzyme 
was found in DM and No-DM patients undergoing PD. The accumulated scientific 
evidence suggests that the main antioxidant systems are impaired in patients on 
PD [32]; possibly the previous finding could be explained in an attempt to com-
pensate the oxidative state that characterized the patients included in the study. 
Antioxidants can be divided into intracellular and extracellular antioxidants. The 
intracellular enzymatic antioxidants are SOD, catalase, and glutathione peroxidase, 
which convert substrates (anion radicals O2− and H2O2) into less reactive forms. 
The first line of defense against free radicals is SOD. Free radicals are the source 
of lipid peroxidation derived from oxygen, and the function of SOD is to catalyze 
the conversion of O2− radicals into H2O2. Therefore, if the activity of SOD in PD 
had been found to be decreased, it would suggest accumulation of the O2− radical 
Antioxidants
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anion responsible for the increase in lipid peroxidation [21]; however, in the 
patients included in the study, SOD was found to be significantly increased and 
TAC decreased in patients undergoing PD with DM and No-DM, which could sug-
gest that peritoneal replacements could purge the systemic buffering levels of the 
TAC. In a recently reported study, the authors underwent to hemodialysis session 
in patients with ESRD; they found a significant reduction in TAC according to our 
findings [33]. The depletion of TAC found in patients undergoing PD is contrary to 
that reported by other authors in relation to increased levels of these systemic buf-
fers in patients undergoing hemodialysis. [34]. The concentrations of bilirubin, uric 
acid, and plasma albumin are the main defense in the extracellular fluids generated 
during the normal metabolism or are ingested by the consumption of dietary prod-
ucts rich in antioxidants [35]. These extracellular antioxidants prevent the reaction 
of free radicals by sequestering transition metal ions by plasma chelation [36]; the 
TAC is able to determine these extracellular antioxidants. In the present study, TAC 
was found to be significantly consumed in all patients included.
The addition of exogenous antioxidants to the management of patients who are 
in PD is an incomplete and little studied subject; however, this topic is interesting 
that is well worth considering in these patients. In a report of the literature, the 
authors studied the N-acetylcysteine (NAC) which is considered as a potential anti-
oxidant with anti-inflammatory effects for dialysis patients. Vitamin C could play 
an important role in helping PD patients to use iron for erythropoiesis and achieve 
better hemoglobin response during the treatment of anemia [37].
5. Conclusions
When comparing patients in PD according to the presence or absence of DM, we 
found imbalance of markers of oxidative stress characterized by increased LPO prod-
ucts, serum decrease of 8-PI, dysregulation of the antioxidant defense system with 
significant decrease in TAC, and increase in SOD possibly in an attempt to compensate 
for the state of oxidative stress. In this population, increased levels of triglycerides and 
VLDL were observed, which favors the appearance of accelerated atherosclerosis with 
an increase in arterial stiffness, as well as a decrease in NO levels, which favors second-
ary endothelial dysfunction. These factors contribute to the increase of CVD in PD 
patients. Supplementation with external antioxidants could be an emerging strategy to 
counteract OS with the potential to preserve peritoneal function.
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